Clinical Trials Browser

OTHER × tremelimumab × Clear all

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Phase EARLY_PHASE1 Active not recruiting

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Liver Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06904170 2026-02-03

ALICE

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Phase 2 Active not recruiting

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Liver Neoplasms

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT05380713 2025-12-29

......SMARTEST Trial......

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Phase 2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06698250 2025-11-06

ZENOBIA

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06058663 2025-10-20

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1/2 Recruiting

Other solid neoplasmThoracic

Mesothelioma

NCT03026062 2025-09-19

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Phase 1 Completed

13 enrolled 12 charts

Head and Neck Neoplasms

NCT04605731 2025-09-10

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06999694 2025-09-10

Proton-STRIDE

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02962063 2025-09-05

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07122089 2025-08-14

IOSPHERE

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02029001 2025-08-07

MOST plus

Phase 2 Recruiting

Neoplasm Metastasis

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02815995 2025-06-12

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Phase 2 Completed

57 enrolled 18 charts

Hemangiosarcoma, Leiomyosarcoma, Osteosarcoma, Sarcoma, Synovial, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Histiocytoma, Malignant Fibrous

NCT04817826 2025-06-10

INFINITY

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms, Microsatellite Instability

NCT06999707 2025-06-05

Photon-STRIDE

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Phase 1 Terminated

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06911255 2025-05-14

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03212469 2025-05-08

ABIMMUNE

Phase 1/2 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT04585490 2025-05-06

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT03601455 2025-04-13

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT06045975 2025-04-02

DUMELEP

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03871036 2025-03-06

ICRA

Phase 1/2 Completed

Carcinoma, Transitional Cell

NCT06710223 2025-02-11

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03317158 2025-01-30

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03095274 2025-01-09

DUNE

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

NCT03802747 2024-12-09

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Phase 1 Withdrawn

Gastrointestinal

Colorectal Neoplasms